AXA in July 2016 announced the appointment of Matthieu André as CEO of AXA Global Life & Savings, reporting to Paul Evans who is in charge of AXA’s life, savings, protection and health activities on a global basis. Matthieu André joined AXA in 1995 as a financial controller after a spell as an auditor and consultant with Ernst & Young. His career path included positions as VP, Corporate Finance

The emergence of new, more expensive, cancer drug therapies that help the immune system attack tumors is expected to increase cancer drug spending to over $150 billion by 2020 according to a global oncology report released by IMS Health Holdings. This represents an annual global growth rate for oncology drug spending of 7.5% to 10.5% through 2020, up from last year’s IMS forecast of 6% to 8% growth. The

PPG Industries, the Pittsburgh-based coatings, specialty materials, and glass products manufacturer, in April 2016 announced that they will begin buying group annuity contracts in order to provide pension benefits to 13,000+ retirees and survivors in the U.S.A. PPG joins such large corporations as Kimberly-Clark Corp., Verizon, and General Motors, who have adopted this de-risking process in order to reduce premium payments to the Pension Benefit Guaranty Corp (PBGC). PBGC

UK employers tend to fall short when it comes to having a defined health strategy plan for their employees, especially when the numbers are measured against mainland Europe, Middle East, and Africa (EMEA). Aon’s EMEA Health Survey Report, published in early 2016, revealed that only 30 percent of UK employers have a defined health strategy compared with 40 percent of EMEA employers, and that only 37% of UK employers